Decreasing the large test variability associated with measurements of blood cholesterol, triglyceride, and highdensity lipoprotein (HDL)-and low-density lipoprotein (LDL)-cholesterol is likely to improve the classification of coronary heart disease (CHD) risk and allow improved monitoring of lipid-lowering treatments. However, improving test precision will benefit the clinician only if (a) the analytical test variability is high relative to the biological test variability and (b) detecting subtle responses to diet or drug therapy is clinically important. further evaluation (4).
further evaluation (4) .
These recommendations placed increased demands on total cholesterol, serum triglyceride, and high-density lipoprotein (HDL) cholesterol measurements to be as accurate and reproducible as possible. Imprecise measurements will impair the correct classification of CHD risk increasing the frequency of either over-or under-treatment. Further, high test variability may limit the clinician's ability to detect an important response to therapy or to determine a meaningful reduction in CHD risk. Our purpose here is to assess whether the analytical and biological variability usually associated with these lipid measurements interferes with their clinical usefulness, and to evaluate the extent that reductions in test variability will improve the clinician's ability to evaluate and treat lipid disorders.
Upld and Upoproteln Test VarIability: DefInition and ClInical SIgnIficance
The test variability associated with lipid and lipoprotein measurements has two components. The first component is the natural biological variability (Vb), which may be influenced by many factors, including recent diet, day of the week or season, illness, and postural changes ( Table 1 ). The second component is the analytical variabifity (Va) due to the imprecision of the assay.
These values are usually expressed as a coefficient of variation (CV, CVb) around the test mean. The total test variability is also expressed as a coefficient of variation (CVi). The total test variability (CVi) is defined (6) as (CV)2 = (Ta)2 + (7)2
To reduce the CV of any test, three approaches can be considered. First, the CV can be decreased by improving the reliability of the assay in the clinical laboratory.
The Laboratory Standardization Panel of the NCEP has set standards for total-cholesterol measurements (3), and others have suggested that similar requirements be established for other lipid measurements (7) . Analytic VariabilIty (%) Variability. Figure 1 shows the effect of increasing analytical precision of total-cholesterol measurements on the total variability. Assuming a biological CV of 6.5% (12) , decreasing the CVa from 5% to 3% will reduce the CV by 1.2%. However, when the analytical vanability is lowered to <3%, negligible reductions in total test variability are achieved. Figure 2 shows the effect of replicate measurements on the CVI, assuming a test precision of 3%. At Because of the high biological variability, the CV usually exceeds 20% (Figure   1 ).
Multiple samplings, or minimizing biological variability, or both, are therefore necessary to reduce total test variability.
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Number ef Replicate Measurements Fig.3 . Effect of repeatedmeasurements to reduceblood triglyceride variability Symbols as in Fig. 2 would be required (Figure 5 ).
HDL-Cholesterol
The right-hand side of Figure 5 showsresults from an HDL assay with improved analytical precision (analytical CV = 3%). With this improved test, only 21% of total test variability is ascribable to analytical variability. Because the analytical imprecision is already low, performing the assay in duplicate or triplicate confers little benefit. However, the total test variability has been decreased to <7% with one specimen, and only two specimens are necessary to decrease it to <5%. Improving analytical precision in this case does reduce the total test variability, limiting the need for multiple specimens. In summary, a significant component of variability of HDL-cholesterol measurements is due to the analytical imprecision of the test. Because HDL-cholesterol is a strong inverse predictor of CIII) risk, and because most drug and diet interventions produce only small increases ( 15%) in HDL-cholesterol, the ability to reliably detect small changes in HDL-cholesterol is desirable. Improving the precision of the test will improve the clinician's ability to accurately assess CHD risk, and will also allow a more reliable assessment of response to diet and drug therapy.
LDL-Cholesterol
Importance.
LDL Fig.2 whether by diet or drug therapy, decreases the incidence of CIII). 10% (19, 20) . These components of variability contribute to a total test variability of -11% (Figure 6 ). To decrease the CV to <5%, evaluation of five blood specimens is necessary ( Figure 6A Figure 6B demonstrates the potential advantages of using an improved method of LDL separation to measure LDL-cholesterol directly. Direct measurement of LDL-cholesterol offers the potential to improve both analytical and biological variability, because the precision of the LDL measurement would not depend upon the analytical and biological variability present in measurements of triglyceride, total-, and HDL-cholesterol. In this hypothetical example, the analytical variability is decreased to 3%, the biological variabifity to 5%. The total test variability of one measurement is decreased to 6%, and only two measurements are required to reduce it to <5% (Figure 6 ). 
